AI startup Chai Discovery inks GSK deal to develop biologics using artificial intelligence

Chai Discovery, an artificial‑intelligence focused biotech, has signed a collaboration agreement with GlaxoSmithKline to create biologic medicines using its AI platform.

The partnership will leverage Chai's machine‑learning tools to accelerate the design and optimization of protein‑based therapeutics, aiming to shorten development timelines and reduce costs.

This agreement marks the sixth pharmaceutical partnership the company has secured in the past nine months, following earlier collaborations with firms such as Eli Lilly earlier in 2026.